Strengthening the global revenue base
First written in FY2016. 22 of 37 entries say "Restated". Latest entry: FY2026.
- FY2026AdvancedAnnual report
「Medical sales increased in all regions in both Japan and overseas. Overseas sales increased in both the cardiovascular and non-cardiovascular fields, with foreign exchange movements also contributing. As a result, sales rose to ¥126.798 billion, up 17.6% year on year.」
Medical sales increased in all regions in Japan and overseas, with sales rising to ¥126.798 billion, up 17.6% year on year. - FY2026-H1AdvancedAnnual report
「Medical Business net sales increased in all regions in both Japan and overseas markets. In overseas markets, sales increased in both the cardiovascular and non-cardiovascular fields. As a result, net sales amounted to ¥6,266.5 million, up 12.4% year on year.」
Medical Business net sales increased in all regions in Japan and overseas, resulting in net sales of ¥6,266.5 million for the interim period, up 12.4% year on year. - FY2025AdvancedAnnual report
「The Group currently supplies products to 121 countries and regions worldwide. In this environment, we intend to strengthen our earnings base on a global scale by further enhancing our sales and marketing functions in each region.」
The Group has expanded its product supply footprint from more than 118 to 121 countries and regions and continues to pursue a policy of enhancing sales and marketing functions in each region. - FY2025-H1RestatedAnnual report
「① Strategic development of global markets and expansion into new anatomical sites and treatment areas」
The Group continues to develop global markets and expand its treatment areas as basic policies under ASAHI Going Beyond 1000. - FY2024AdvancedAnnual report
「The Group’s net sales for the consolidated fiscal year increased 19.4% year on year to ¥10,754.7 million, as overseas sales grew significantly, reflecting the increase in cases accompanying the recovery from the COVID-19 pandemic, continued efforts to expand market share and the impact of a stronger foreign currency.」
Overseas sales increased while the Group pursued market share expansion, resulting in consolidated net sales of ¥10,754.7 million, up 19.4% year on year. - FY2024-Q3AdvancedAnnual report
「In overseas markets, net sales increased in all fields, including cardiovascular, non-cardiovascular and OEM transactions. As a result, net sales amounted to ¥7,160.7 million, up 17.2% year on year.」
All fields in overseas markets, including cardiovascular, non-cardiovascular and OEM, recorded increases, and Medical Business net sales amounted to ¥7,160.7 million, up 17.2% year on year. - FY2024-Q2AdvancedAnnual report
「In overseas markets, sales increased in all regions in both the cardiovascular and non-cardiovascular fields.」
Sales in the cardiovascular and non-cardiovascular fields in overseas markets increased in all regions, and Medical Business net sales amounted to ¥4,836.9 million, up 21.9% year on year. This indicates progress during the six months ended the second quarter in strengthening the earnings base on a global scale. - FY2024-Q1AdvancedAnnual report
「In overseas markets, sales increased in all regions in both the cardiovascular and non-cardiovascular fields. As a result, net sales amounted to ¥2,559 million, up 29.7% year on year.」
Sales in both the cardiovascular and non-cardiovascular fields increased in all overseas regions, and Medical Business net sales amounted to ¥2,559 million, up 29.7% year on year. - FY2023AdvancedAnnual report
「The Group currently supplies products to 118 countries and regions worldwide. In this environment, we intend to strengthen our earnings base on a global scale by further enhancing our sales and marketing functions in each region.」
The Group has expanded its product supply footprint from more than 110 to 118 countries and regions and has indicated a policy of strengthening sales and marketing functions by region. - FY2023-Q3RestatedAnnual report
「As part of the construction of our business portfolio, we will continue to pursue “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” thereby completing our existing basic strategy and strengthening the earnings base of our existing businesses.」
The Company continues to strengthen the earnings base of its existing businesses through strategic development of global markets and expansion of affected areas and treatment fields. - FY2023-Q2RestatedAnnual report
「As part of the construction of our business portfolio, we will continue to pursue “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” thereby completing our existing basic strategy and strengthening the earnings base of our existing businesses.」
We continue to strengthen the earnings base of our existing businesses by developing global markets and expanding into new anatomical sites and treatment areas. - FY2023-Q1RestatedAnnual report
「As part of the construction of our business portfolio, we will continue to pursue “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” thereby completing our existing basic strategy and strengthening the earnings base of our existing businesses.」
The Company continues to strengthen the earnings base of its existing businesses through strategic development of global markets and expansion of affected areas and treatment fields. - FY2022-Q2RestatedAnnual report
「As part of the construction of our business portfolio, we will continue to pursue “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” thereby completing our existing basic strategy and strengthening the earnings base of our existing businesses.」
We continue to strengthen the earnings base of our existing businesses by developing global markets and expanding into new anatomical sites and treatment areas. - FY2021RestatedAnnual report
「The Group currently supplies products to 110 countries and regions worldwide. In this environment, we intend to strengthen our earnings base on a global scale by further enhancing our sales and marketing functions in each region.」
Based on supplying products to 110 countries and regions, the Group continues to pursue a policy of strengthening its earnings base by enhancing sales and marketing functions in each region. - FY2021-Q3RestatedAnnual report
「By pursuing “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” we aim to complete our existing basic strategy and strengthen the earnings base of our existing businesses.」
We continue to strengthen the earnings base of our existing businesses by developing global markets and expanding into new anatomical sites and treatment areas. - FY2021-Q2RestatedAnnual report
「By pursuing “the strategic development of global markets and expansion into new anatomical sites and treatment areas,” we aim to complete our existing basic strategy and strengthen the earnings base of our existing businesses.」
Under ASAHI Road to 1000, the Company continues to strengthen the earnings base of its existing businesses through development of global markets and expansion of affected areas and treatment fields. - FY2021-Q1RestatedAnnual report
「As part of building a business portfolio aimed at achieving ¥100 billion in consolidated net sales, the Company will pursue “strategic development of global markets and expansion of affected areas and treatment fields,” thereby consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
The Company continues to strengthen the earnings base of its existing businesses through strategic development of global markets and expansion of affected areas and treatment fields. - FY2020RestatedAnnual report
「Based on the five-year medium-term management plan “ASAHI Road to 1000: Aiming to become a strong global niche No. 1 through Only One technology,” the Group is pursuing “strategic development of global markets and expansion of affected areas and treatment fields” as it builds a business portfolio aimed at achieving ¥100 billion in consolidated net sales. Through this initiative, it is consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
Under ASAHI Road to 1000, the Company continues to strengthen the earnings base of its existing businesses through development of global markets and expansion of affected areas and treatment fields. - FY2020-Q3RestatedAnnual report
「Based on the five-year medium-term management plan “ASAHI Road to 1000: Aiming to become a strong global niche No. 1 through Only One technology,” the Group is pursuing “strategic development of global markets and expansion of affected areas and treatment fields” as it builds a business portfolio aimed at achieving ¥100 billion in consolidated net sales. Through this initiative, it is consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
The Company continues to strengthen the earnings base of its existing businesses through strategic development of global markets and expansion of affected areas and treatment fields. - FY2020-Q2RestatedAnnual report
「As part of building a business portfolio aimed at achieving ¥100 billion in consolidated net sales, the Company will pursue “strategic development of global markets and expansion of affected areas and treatment fields,” thereby consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
The Company continues to pursue its policy of strengthening the earnings base of existing businesses through strategic development of global markets and expansion of affected areas and treatment fields. - FY2020-Q1RestatedAnnual report
「As part of building a business portfolio aimed at achieving ¥100 billion in consolidated net sales, the Company will pursue “strategic development of global markets and expansion of affected areas and treatment fields,” thereby consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
The Company continues to strengthen the earnings base of its existing businesses through strategic development of global markets and expansion of affected areas and treatment fields. - FY2019RestatedAnnual report
「As part of building a business portfolio aimed at achieving ¥100 billion in consolidated net sales, the Company will continue to pursue “strategic development of global markets and expansion of affected areas and treatment fields,” thereby consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
Under ASAHI Road to 1000, the Company continues to strengthen the earnings base of its existing businesses through strategic development of global markets and expansion of affected areas and treatment fields. - FY2019-Q3RestatedAnnual report
「As part of building a business portfolio aimed at achieving ¥100 billion in consolidated net sales, the Company will continue to pursue “strategic development of global markets and expansion of affected areas and treatment fields,” thereby consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
The Company continues to strengthen the earnings base of its existing businesses through strategic development of global markets and expansion of affected areas and treatment fields. - FY2019-Q2RestatedAnnual report
「As part of building a business portfolio aimed at achieving ¥100 billion in consolidated net sales, the Company will continue to pursue “strategic development of global markets and expansion of affected areas and treatment fields,” thereby consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
Under ASAHI Road to 1000, the Company continues to strengthen the earnings base of its existing businesses through strategic development of global markets and expansion of affected areas and treatment fields. - FY2019-Q1RestatedAnnual report
「As part of building a business portfolio aimed at achieving ¥100 billion in consolidated net sales, the Company will continue to pursue “strategic development of global markets and expansion of affected areas and treatment fields,” thereby consolidating its basic strategies to date and strengthening the earnings base of its existing businesses.」
Under the new medium-term management plan, the Company continues to strengthen the earnings base of its existing businesses through strategic development of global markets and expansion of affected areas and treatment fields. - FY2018ReframedAnnual report
「By continuing to pursue “strategic development of global markets and expansion of affected areas and treatment fields,” the Company will consolidate its basic strategies to date and strengthen the earnings base of its existing businesses.」
The former policy of “strengthening the earnings base on a global scale” has been reorganized under the new medium-term management plan as strengthening the earnings base of existing businesses through strategic market development and expansion of treatment fields. - FY2018-Q2RestatedAnnual report
「The Group’s net sales for the cumulative second quarter of the current consolidated fiscal year remained supported by firm demand, with overseas sales in the Medical Business increasing in particular to ¥25.409 billion, up 24.5% year on year.」
The Company reported increased overseas sales in the Medical Business, consolidated net sales of ¥25.409 billion and year-on-year growth of 24.5%. - FY2018-Q1AdvancedAnnual report
「The Group’s net sales for the cumulative first quarter of the current consolidated fiscal year remained supported by firm demand, with overseas sales in the Medical Business increasing in particular to ¥12.568 billion, up 25.8% year on year.」
In connection with strengthening the earnings base on a global scale, overseas sales in the Medical Business increased, driving consolidated net sales up 25.8% year on year. - FY2017RestatedAnnual report
「(a) Strengthening the earnings base on a global scale」
The Company continues to pursue strengthening its earnings base on a global scale as a basic policy of its medium-term management plan. - FY2017-Q3RestatedAnnual report
「1. Strengthening the earnings base on a global scale」
The Company continues to pursue strengthening its earnings base on a global scale as a basic policy of its medium-term management plan. - FY2017-Q2RestatedAnnual report
「1. Strengthening the earnings base on a global scale」
The Company continues to pursue strengthening its earnings base on a global scale as a basic policy of Global Expansion 2018. - FY2017-Q1RestatedAnnual report
「1. Strengthening the earnings base on a global scale」
The Company continues to pursue strengthening its earnings base on a global scale as a basic policy of its medium-term management plan. - FY2016First statedAnnual report
「Strengthening the global revenue base」
One of the 4 basic policies of Global Expansion 2018. The policy calls for enhancing sales and marketing functions in each region.